据灯塔专业版实时数据，截至2月23日20时26分，影片《镖人：风起大漠》票房突破8亿。

CenterPoint Energy ( CNP ) said it plans to offer $550M in convertible senior notes due 2029 through a private placement to qualified institutional buyers. The company also expects to give initial purchasers the option to buy up to an additional $50M of the notes within 13 days after the initial issuance, subject to market conditions. The convertible notes will mature on May 15, 2029, unless earlier converted or repurchased. CenterPoint intends to use the net proceeds from this offering for general corporate purposes, including the repayment of a portion of its outstanding commercial paper and other debt. CNP shares fell -2.7% premarket. More on CenterPoint Houston, We Have A Winner In CenterPoint Energy CenterPoint Energy, Inc. 2025 Q4 - Results - Earnings Call Presentation CenterPoint Energy, Inc. (CNP) Q4 2025 Earnings Call Transcript CenterPoint sees 8% EPS growth in 2026 and accelerates $500M capital plan amid Houston load surge CenterPoint Non-GAAP EPS of $0.45 in-line; reaffirms FY26 outlook

格隆汇2月23日｜据央视，当地时间23日，据伊拉克外交部声明，伊拉克副总理兼外交部长侯赛因当天在巴格达会见了美国总统特使汤姆·巴拉克及其随行代表。侯赛因表示，伊拉克正持续与多国沟通，将涉嫌恐怖主义案件的外籍公民遣返回国，并提及土耳其政府已同意接收土耳其籍人员。双方还讨论了伊朗与美国间关系及美伊谈判进展。侯赛因强调，任何潜在冲突或战争将对整个地区构成严重影响。伊拉克支持美伊采取和平途经，并坚定支持将于26日在日内瓦举行的美伊新一轮谈判。双方还就伊拉克新一届政府组建和总理提名等议题进行了讨论。侯赛因重申，伊拉克政府组建是伊拉克的内政。在新一届政府组建完成前，各方需要继续保持沟通与协调。

The hardware and home-furnishings rivals will both report quarterly results this week.

So much has happened this year and yet the market is implying that not much has changed. War warnings, policy reversals, the hunt for AI victims, more than one putative $1 trillion private company looming over the public markets – there's plenty going on. But in aggregate, portfolios and the economic backdrop are largely unmoved. The S & P 500 is piling up the superlatives to describe its extreme stasis. On more than 40% of all trading sessions the past two months, the index has crossed the 6,900 level – which it first touched way back on Oct. 28. The benchmark's traded in the narrowest range by this point in February in 60 years, according to Bespoke Investment Group. The Bollinger Bands that define the index's prevailing trend are closer together than they've been for five years, a picture of a market coiling tightly. .SPX 6M mountain S & P 500, 6 months The economy remains in a familiar mode, too. It grew last year at about a 5% nominal rate, with a bit more from inflation than real-output gains, which also pretty closely describes the economy of 2024. The corporate capex chase for "superintelligence" is having a blunt-force impact on economic activity again. Consumer spending is being supported, still, by upper-income asset owners and an aging population operating in a service-centric economy. Don Rissmiller, chief economist at Strategas Research, frames the market's layered dependencies like this: "This chain is likely to be a recurring theme in 2026: the U.S. economy is dependent on the stock market, the stock market is dependent on the bond market, and the bond market is dependent on the tug of war between the commodity market (pushing inflation higher) vs. productivity (holding inflation & unit labor costs down)." Corporate earnings are on pace to close out a fifth straight quarter of double-digit percentage gains, a positive but unchanging pace that clearly is now being fully anticipated by investors before the reports hit. The Supreme Court's invalidation ...

Labcorp ( LH ) on Monday said it will expand its collaboration with PathAI to deploy the FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations. Labcorp said the cloud-based platform will support fully digital workflows for slide review, case management and collaboration, and integrate AI-powered image analysis to assist in diagnostics. The company said it will also incorporate digital pathology workflows to support its precision medicine products. The expansion builds on Labcorp’s 2019 strategic investment in PathAI and follows ongoing collaboration in AI-driven clinical trial support and validation of AI-pathology solutions. LH +1.59% premarket to $287.17. Source: Press Release More on Labcorp Holdings Labcorp Holdings Inc. (LH) Q4 2025 Earnings Call Transcript Labcorp Holdings Inc. 2025 Q4 - Results - Earnings Call Presentation Labcorp Holdings Inc. (LH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Labcorp outlines 5.4% midpoint revenue growth and 9% EPS target for 2026 while advancing specialty and AI initiatives Labcorp slips after Q4 revenue miss

Foghorn Therapeutics ( FHTX ) said on Monday that Ryan Maynard will join the clinical-stage biotech as CFO effective Feb. 23, 2026. Maynard brings over 25 years of executive experience in biopharma and healthcare technology, has raised more than $1 billion in public and private financings, and most recently served as CFO of Cara Therapeutics. He currently serves on the board of Iovance Biotherapeutics. Shares -1.72%. More on Foghorn Therapeutics Seeking Alpha’s Quant Rating on Foghorn Therapeutics Historical earnings data for Foghorn Therapeutics Financial information for Foghorn Therapeutics

Md Babul Hosen/iStock via Getty Images PTC Therapeutics ( PTCT ) is entering a new phase of growth as newer products begin to replace older revenue sources. I believe the recent launch of Sephience, an oral therapy approved for the treatment of phenylketonuria (PKU), a rare genetic disorder that prevents patients from properly metabolizing the amino acid phenylalanine, could become the company's primary driver of revenue expansion over the next several years. Although recent financial comparisons are affected by the sale of Evrysdi royalties, the underlying business appears to be strengthening, which may not yet be fully reflected in the company's valuation. PTC Therapeutics is a biopharmaceutical company operating in both commercial and clinical stages that is focused on developing drugs for rare genetic diseases, where there is a large unmet need for treatment. Their initial focus was in the area of small molecule drug discovery targeting post-transcriptional control and splicing and has now expanded to include many other types of drugs, including gene therapies. It still uses its current development model by using primarily oral small molecules and collaborating with other organizations to reduce development costs and excel at distribution. Traditionally, PTC's revenue base was driven largely by older drugs such as Translarna and Emflaza for Duchenne muscular dystrophy (DMD) and Evrysdi , a splicing modifier invented and sold with Roche for spinal muscular atrophy (SMA). Although those drugs are continuing to generate revenues for PTC, much of PTC's revenue growth is now due to newer drugs such as Sephience for phenylketonuria (PKU) and Kebilidi /Upstaza, a gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency. Sephience Drives Financial Momentum PTC's most significant recent growth has been due to the commercial launch of Sephience, which was approved by the U.S. FDA for the treatment of PKU in July 2025, making it one of the first oral therapie...

美国贸易政策前景不明令市场情绪承压，美国股指期货下跌。美元收复失地，贵金属走高。 标普500指数期货下跌0.3%。在最高法院推翻总统唐纳德·特朗普的紧急关祱后，投资者正评估新的15%全球关祱可能带来的影响。美元收复了0.3%的跌幅。黄金在连续三周上涨后继续走高。比特币短暂跌破65，000美元。 关祱问题为本已因人工智能颠覆性影响及中东紧张局势升温而动荡的市场增添更多不确定性。本周开局谨慎，投资者关注周二特朗普的国情咨文演讲，以及周三的英伟达财报，两者均可能成为重要催化剂。 “市场很快意识到，该裁决短期内可能不会带来太大改变，反而会增加不确定性，” BNP Paribas Wealth Management首席投资策略师Stephan Kemper表示。“唐纳德·特朗普素来不回避斗争或轻易放弃。” 欧洲股市走势反复。斯托克600指数在早些时候收窄跌幅后再度走低，受制于 诺和诺德 表示其减肥药Cagrisema在一项试验中不及 礼来 的竞争产品。诺和诺德在哥本哈根暴跌15%，礼来在美国盘前上涨逾3%。 纳斯达克 100指数期货下跌0.4%。美国国债小幅走高，10年期收益率跌1个基点至4.07%。随着一场冬季风暴席卷美国东北部，美国天然气价格上涨。 责任编辑：郭明煜

klmax/iStock via Getty Images Wrap Technologies, Inc. ( WRAP ) is a safety technology company aiming to build an integrated non-lethal response platform. This includes their BolaWrap 150 restraint device, training and software offerings, and body-worn cameras for video and evidence workflows. Recently, the company raised an extra $5 million to restart its domestic manufacturing, expand training capacity, and push next-generation programs toward commercialization. Unfortunately, despite some promising signs (revenue and subscription growth), I still don't think WRAP justifies a bullish rating at these levels. Struggling Safety Tech Wrap Technologies, Inc. is a technology company that develops less-lethal and non-lethal tools. Their applications are intended to help with training for law enforcement and other security users like corrections, military, and private protection around the globe. WRAP became a public company back in 2017 and is currently headquartered in Miami, Florida. I also previously covered WRAP last October. However, since then, the stock has declined by roughly 34.7%, so I thought it was worthwhile writing an update on this name. Source: Wrap Technologies, Inc. Website. Retrieved February, 2026. As a quick recap, WRAP focuses on researching and producing its restraint devices with training and supporting software and services. WRAP's main product is the BolaWrap 150 , which is a remote restraint device that's designed to avoid escalation and safer outcomes with reduced injuries. The BolaWrap is a handheld device that uses a tether-based entanglement mechanism. The latest iteration of this product now has operational improvements in size and weight, durability, water resistance, indicators, and illumination, among others. Portfolio Prospects Additionally, WRAP's product portfolio has complementary offerings like Wrap Reality and Intrensic. Wrap Reality is a virtual reality (VR) platform for training using scenarios to instruct in de-escalation, decis...

An antiques dealer realised they were Napoleonic by the markings he recalled seeing on TV show Lovejoy.

Veris Residential press release ( VRE ): Q4 FFO of $0.19 beats by $0.03 . Revenue of $71.31M (+4.7% Y/Y) beats by $0.39M . More on Veris Residential Top 10 small-cap stocks with highest dividend growth grade Veris Residential gains on report holder pushes for sale Seeking Alpha’s Quant Rating on Veris Residential Historical earnings data for Veris Residential Dividend scorecard for Veris Residential

Sergei Dubrovskii/E+ via Getty Images Tidewater ( TDW ) +3.5% pre-market Monday after saying it agreed to acquire Wilson Sons Ultratug Participacoess and its affiliate Atlantic Offshore Services in a deal worth ~$500M including debt. Tidewater ( TDW ) said the acquisition will strengthen its position in offshore supply vessels, as WSUT's fleet consists of 22 platform supply vessels; following the transaction, Tidewater will own a fleet of 213 OSVs, bringing its total global fleet size to 231 vessels, including crew boats, tugboats, and maintenance vessels. The deal also will e xpand Tidewater's ( TDW ) current fleet of six vessels in Brazil to 28, providing meaningful scale and the operational capability required to support the continued growth of the Brazilian offshore energy market, the company said. " As we've surveyed the world and evaluated different regions, Brazil stands out as perhaps the most attractive to Tidewater," President and CEO Quintin Kneen said. "The scale of the offshore industry in Brazil , and in particular the offshore vessel industry, is one of the best in the world, and we believe the long-term fundamentals for this market are highly favorable." More on Tidewater Tidewater: M&A Or Buybacks In Sight Tidewater: Rational To Trade Short Term, Otherwise Sell Rating Maintained Seeking Alpha's Quant Rating on Tidewater

NVIDIA Corporation $NVDA Shares Acquired by Tyche Wealth Partners LLC MarketBeat

Apple Inc. $AAPL Shares Bought by Whittier Trust Co. MarketBeat

Welch & Forbes LLC Decreases Stock Position in NVIDIA Corporation $NVDA MarketBeat

Tesla, Inc. $TSLA Shares Sold by Legacy Financial Advisors Inc. MarketBeat

Vanguard Group Inc. Has $141.53 Billion Stock Holdings in Meta Platforms, Inc. $META MarketBeat

Werba Rubin Papier Wealth Management Has $24.61 Million Stock Holdings in NVIDIA Corporation $NVDA MarketBeat

Amazon.com, Inc. $AMZN is Veritas Asset Management LLP's 2nd Largest Position MarketBeat

Meta Platforms, Inc. $META Shares Bought by Zions Bancorporation National Association UT MarketBeat

Bagsværd, Denmark, 23 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programm

(RTTNews) - Labcorp Holdings, Inc. (LH), a comprehensive laboratory services provider, announced Monday an expanded collaboration with PathAI to deploy AISight Dx, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital colla

Herbalife ( HLF ) on Monday said that it plans to refinance its senior secured debt with a targeted $1.55 billion financing package. The company said the refinancing is expected to include a $425 million revolving credit facility, a $125 million Term Loan A, a $500 million Term Loan B and $500 million of other secured debt, and would extend the maturity profile of its senior secured debt. Herbalife said it has initiated the refinancing process for its Term Loan B due April 2029, under which $370 million was outstanding as of December 31, 2025. The company said the proposed transactions are subject to customary closing conditions and there is no assurance they will be completed. HLF +0.05% premarket to $19.97. Source: Press Release More on Herbalife Herbalife's Turnaround Accelerates With Ronaldo's Pro2col Herbalife Ltd. (HLF) Q4 2025 Earnings Call Transcript Herbalife Ltd. 2025 Q4 - Results - Earnings Call Presentation Herbalife outlines 1%–6% 2026 net sales growth target as Cristiano Ronaldo invests in Pro2col Herbalife Q4 2025 Earnings Preview

(RTTNews) - Dream Finders Homes, Inc. (DFH) announced earnings for fourth quarter that Dropped, from the same period last year

在通往完全无人驾驶的漫长道路上，车企正竞相冲刺一个关键里程碑：推出允许驾驶员 视线脱离路面 的驾驶系统 —— 驾驶员可以发短信、操作笔记本电脑，只有在车辆发出接管提醒时才需要重新掌控车辆。 多年来，车企一直在升级可自动控制车速与转向的驾驶辅助系统。让驾驶员在驾驶时处理其他事务，或将成为下一步发展方向，帮助车企从巨额自动驾驶投入中实现盈利。 福特汽车 首席电动车、数字化及设计官道格・菲尔德表示：“我们可以立刻为用户节省时间，而且成本亲民。” 福特计划从 2028 年开始，在平价电动车型上搭载视线脱离路面系统。 但行业内对这项被称为 L3 级自动驾驶 的视线脱离技术是否值得量产，争议日益加剧。部分高管与行业专家认为，在车辆与人类驾驶员之间频繁切换控制权既不现实也不安全，还会引发棘手的责任认定问题。 也有人质疑，是否有足够多的消费者愿意为这项技术买单，以覆盖高昂的研发成本。 汽车供应商博世北美业务总裁保罗・托马斯在 1 月 CES 消费电子展上对路透社表示：“我们不确定 L3 级自动驾驶在商业上是否真的划算。” 多家企业放缓 L3 研发进程 十年前，车企高管曾预测自动驾驶汽车如今会遍地普及，但技术难题、成本超支与监管不确定性，导致大规模落地一再推迟。在此期间，车企将完全无人驾驶的核心技术打包成功能越来越强的驾驶辅助系统，但这些系统仍需要人类持续监控。 视线脱离的 L3 系统处于行业自动驾驶分级的中间位置：从 L1 级定速巡航等基础功能，到 L5 级全场景无人驾驶。 目前，市面上几乎所有驾驶辅助系统（包括 特斯拉 完全自动驾驶 FSD）都属于 L2 级系统 ，要求驾驶员时刻观察路况。除福特外，宣布计划推出 L3 视线脱离技术的车企还包括 通用汽车 、本田。 咨询公司麦肯锡近期对行业机构的调研显示，开发一套高速公路场景 L3 系统的成本最高可达 15 亿美元 ，大约是可在城市道路使用的 L2 系统的两倍。 前 Waymo 首席执行官、现任电动车制造商 Rivian 董事约翰・克拉夫奇克表示：“那些尝试过 L3 系统的车企，以及体验过的消费者，都发现得不偿失。” 麦肯锡指出，已有部分企业出于成本考量放弃 L3 研发计划，转而加大投入升级成本更低的 L2 系统。 德国梅赛德斯 - 奔驰是目前唯一在美国推出 L3 技术的车企，但近期因车速限制、使用条件与地理范围约束导致需求不足，暂...